Global Diabetes Market Trends & Future Forecast
Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug)
, Insulin, DPP-IV, GLP-1
Report Details
This report provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering: ( http://www.bharatbook.com/detail.asp?id=144402&rt=Global-Diabetes-Market-Trends-Future-Forecast-Diabetes-Drug-Anti-Diabetic-DrugInsulin-DPP-IV-GLP-1.html )
Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
Region wise Diabetes Health Expenditure and Mortality
Top 10 Countries Diabetes Population and Future Forecast
Top 5 Countries Diabetes Drug Market and Future Forecast
Top 7 Countries Insulin Market and Future Forecast
Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market
Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market
Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market
Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market
Research Highlights
USA controls more than 50% of the total Diabetes Drug market share in 2009
Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
China will have the second highest Insulin market share by 2012 replacing Germany
DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.
Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
Januvia is proving a blockbuster of DPP IV Inhibitors segment expected to be more than US$ 4 Billion by 2017
Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists
China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
Japan Insulin market is expected to be more than US$ 1 Billion by 2010
Key Drugs Analyzed
Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix
Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus
DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus,
GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide
To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=144402&rt=Global-Diabetes-Market-Trends-Future-Forecast-Diabetes-Drug-Anti-Diabetic-DrugInsulin-DPP-IV-GLP-1.html
Related Reports
Diabetes Market Forecast to 2015
http://www.bharatbook.com/detail.asp?id=84122&rt=Diabetes-Market-Forecast-to-2015.html
BRIC Diabetes Drugs Market
http://www.bharatbook.com/detail.asp?id=134449&rt=BRIC-Diabetes-Drugs-Market.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
by:
Think Mobile! Think Application! Think Global! Purchasing An Apartment For Investment Purposes Explaining to Kids About Global Warming Remain Globally Connected Through Satellite Tv Channels It Industry Coming Out Of Global Financial Crisis Don't Be Affected By Global Economic Drawback Decking - Steps To Make The Best Option When Purchasing Surviving An Economy Crisis New Trend: Global Warming Style! Evento global de Governança, Gestão de Risco e Compliance terá participação da True Access Consulting NDM-1 the Newest Global Health Scare The Significant Aspects Of Global Freight Industry Shipping Scale - Choose It Well